Clinical Perspectives: Selecting Between Daratumumab- and Isatuximab-Containing Quadruplet Induction Regimens

Opinion
Video

Panelists discuss how the choice between isatuximab-based quadruplet and daratumumab-based regimens in multiple myeloma treatment depends on clinical trial data comparing Isa-KRd vs KRd, with particular emphasis on efficacy outcomes and patient-specific factors that might influence treatment selection.

Recent Videos
4 experts in this video
4 experts in this video
5 experts are featured in this series
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
5 experts are featured in this series
Related Content